Evidence map›Paper›PMID 39555581›Full record

ReviewFuture oncology (London, England)2024

The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer.

Neal D Shore, Michael S Cookson, Eleni Efstathiou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Neal D ShoreCarolina Urologic Research Center, Myrtle Beach, SC 29572, USA.ORCID 0000-0001-5767-0548
Michael S CooksonThe University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Eleni EfstathiouHouston Methodist Cancer Center, Houston, TX 77030, USA.

Funding

Pfizer PharmaceuticalsSumitomo Pharma Switzerland GmbH
6 · The paper itself

Abstract

In this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration included gonadotropin-releasing hormone receptor agonists (e.g., leuprolide) and antagonists (e.g., degarelix) administered via muscular or subcutaneous injection. In 2020, the once-daily oral gonadotropin-releasing hormone antagonist, relugolix, received US regulatory approval for the treatment of advanced prostate cancer based on results from the Phase III HERO trial. In this podcast, we also discuss the primary efficacy and safety results of this trial, and key points for providers and patients to consider as they discuss the different ADT options.

Indexed as

Androgen AntagonistsAntineoplastic Agents, HormonalProstatic NeoplasmsClinical Trials, Phase III as TopicGonadotropin-Releasing HormoneHumansMaleNeoplasm StagingOligopeptidesTreatment Outcomeacetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamideAndrogen AntagonistsAntineoplastic Agents, HormonalGonadotropin-Releasing HormoneOligopeptidesadvanced prostate cancerandrogen deprivation therapyGnRH agonistsGnRH antagonistspodcastrelugolix

Identifiers

PMID39555581
PMCPMC12266675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.